Hong Lei
- Professor, Neurology - (Clinical Scholar Track)
Contact
- (520) 626-2006
- AHSC, Rm. 6205
- TUCSON, AZ 85724-5023
- leih@arizona.edu
Biography
I have keen interest in patient care, research and teaching. Movement disorder is a field to which I have deep commitment. I am constantly expanding and challenging my knowledge and clinical skills. My expertise in the uses of Botulinum Toxin and Deep Brain Stimulation (DBS) is further enhanced by the trainings and experiences in Ophthalmology, Acupuncture and Aesthetic Medicine.
Degrees
- Ph.D.
- China Medical University, China
- M.D.
- China Medical University
Work Experience
- University of Arizona, Tucson, Arizona (2017 - Ongoing)
- University of Arizona (2011 - 2017)
Awards
- Atwell Award for Research Excellence
- Low Vision Research Group (LVRG), Association for Research in Vision and Ophthalmology (ARVO), USA, Spring 1996
- First Place of Research Excellence Award for the scientific paper presented at the First Youth Scientific Annual Meeting of Chinese Science Union Satellite Conference
- Liaoning Province Youth Academy, Spring 1992
- Outstanding Young Scientist Award
- Liaoning Provincial Government, China, Spring 1992
- Postdoctoral Award for Research Excellence
- Liaoning Provincial Government, China, Spring 1992
- Patients' Choice Award 2015
- Vitals, Winter 2015
- FY15 special recognition award
- Banner-University Medical Group, Spring 2015
Licensure & Certification
- Arizona (2019)
- Arizona (2018)
- Arizona (2020)
- DEA (2019)
- Arizona (2017)
- Certified Ophthalmic Technician (1998)
- DEA (2018)
- DEA (2016)
- Certified Ophthalmic Medical Technologist (2002)
- Diplomat, American Board of Psychiatry and Neurology (2010)
- Diplomat, American Board of Medical Acupuncture (2012)
- California (2006)
- California (2007)
- California (2008)
- Arizona (2007)
- Arizona (2008)
- Arizona (2009)
- Arizona (2010)
- Arizona (2011)
- Arizona (2012)
- Arizona (2013)
- Arizona (2014)
- Arizona (2015)
- Arizona (2016)
- DEA (2007)
- DEA (2006)
- DEA (2009)
- DEA (2008)
- DEA (2011)
- DEA (2010)
- DEA (2013)
- DEA (2012)
- DEA (2015)
- DEA (2014)
Interests
Research
My scientific interests include basic, translational and clinical research in movement disorders.
Teaching
My major interest in teaching is to provide education and training to medical students and other trainees in integrating neurological knowledge, basic examination and decision making skills into patient care.
Courses
2024-25 Courses
-
Neuro+Rehab Med Clerkshp
NEUR 813C (Fall 2024)
2023-24 Courses
-
Neuro+Rehab Med Clerkshp
NEUR 813C (Fall 2023)
2022-23 Courses
-
Neuro+Rehab Med Clerkshp
NEUR 813C (Fall 2022)
2021-22 Courses
-
Neuro+Rehab Med Clerkshp
NEUR 813C (Fall 2021)
2020-21 Courses
-
Neuro+Rehab Med Clerkshp
NEUR 813C (Spring 2021) -
Neurology Clerkship Clinical
NEUR 813C2 (Spring 2021) -
Neuro+Rehab Med Clerkshp
NEUR 813C (Fall 2020)
2019-20 Courses
-
Neuro+Rehab Med Clerkshp
NEUR 813C (Fall 2019)
2018-19 Courses
-
Neuro+Rehab Med Clerkshp
NEUR 813C (Fall 2018)
2017-18 Courses
-
Neuro+Rehab Med Clerkshp
NEUR 813C (Fall 2017)
2016-17 Courses
-
Neuro+Rehab Med Clerkshp
NEUR 813C (Spring 2017) -
Neurology Gen. Inpatient Svc.
NEUR 850A (Spring 2017) -
Research
NEUR 800 (Spring 2017) -
Neuro+Rehab Med Clerkshp
NEUR 813C (Fall 2016)
2015-16 Courses
-
Neuro+Rehab Med Clerkshp
NEUR 813C (Spring 2016)
Scholarly Contributions
Chapters
- Lei, H., & Wang, M. (2015). Sleep Disorders and Neuroregulation. In Eye Diseases Associated with Sleep Disorders(pp 1-15). Hauppauge, NY: Nova Science.
Journals/Publications
- Lundeen, T., Covington, M., Krupinski, E., Avery, R., Lei, H., Sherman, S., & Kuo, P. (2019). Accuracy of Dopamine Transporter Imaging with I-123 Ioflupane in Hispanic and Non-Hispanic Patients. Journal of nuclear medicine technology.More infoRacial and ethnic disparities in the prevalence of neurodegenerative diseases exist. This study examines the agreement between gold standard diagnosis and visual assessment of dopamine transporter (DaT) imaging in Hispanic and non-Hispanic patients being evaluated for Parkinsonian syndromes (PS).
- Lei, H. (2018). Simple Patient Care Instructions Translate Best: Safety Guidelines for Physician Use of Google Translate. Journal of Clinical Outcomes Management.. Journal of Clinical Outcomes Management, 25(1).
- Lei, H., Toosizadeh, N., Schwenk, M., Sherman, S., Karp, S., Sternberg, E., & Najafi, B. (2016). A Pilot Clinical Trial to Objectively Assess the Efficacy of Electroacupuncture on Gait in Patients with Parkinson's Disease Using Body Worn Sensors. PloS one, 11(5), e0155613.More infoGait disorder, a key contributor to fall and poor quality of life, represents a major therapeutic challenge in Parkinson's disease (PD). The efficacy of acupuncture for PD remains unclear, largely due to methodological flaws and lack of studies using objective outcome measures.
- Covington, M. F., Sherman, S., Lewis, D., Lei, H., Krupinski, E., & Kuo, P. H. (2015). Patient Survey on Satisfaction and Impact of 123I-Ioflupane Dopamine Transporter Imaging. PloS one, 10(7), e0134457.More infoPatients were surveyed to assess the impact of dopamine transporter imaging on diagnostic confidence, change in treatment plan, effect on medication compliance, and subjective well-being. Surveys were sent to 140 patients who completed dopamine transporter imaging an average of 18 months prior. Sixty-five surveys from patients (46%) were returned. Questions assessed patients' perceived impact of the imaging on their care. Increased diagnostic confidence following imaging was reported by 69% of patients. Changes to treatment plan from imaging were reported by 24% of patients. Overall satisfaction with the study and its impact was reported by 70% of patients. Dopamine transporter imaging increased diagnostic confidence among patients and overall patient satisfaction with the impact of imaging on clinical care was high.
- Toosizadeh, N., Lei, H., Schwenk, M., Sherman, S. J., Sternberg, E., Mohler, J., & Najafi, B. (2015). Does integrative medicine enhance balance in aging adults? Proof of concept for the benefit of electroacupuncture therapy in Parkinson's disease. Gerontology, 61(1), 3-14.More infoPostural balance and potentially fall risk increases among older adults living with neurological diseases, especially Parkinson's disease (PD). Since conventional therapies such as levodopa or deep brain stimulation may fail to alleviate or may even worsen balance, interest is growing in evaluating alternative PD therapies.
- Toosizadeh, N., Mohler, J., Lei, H., Parvaneh, S., Sherman, S., & Najafi, B. (2015). Motor Performance Assessment in Parkinson's Disease: Association between Objective In-Clinic, Objective In-Home, and Subjective/Semi-Objective Measures. PloS one, 10(4), e0124763.More infoAdvances in wearable technology allow for the objective assessment of motor performance in both in-home and in-clinic environments and were used to explore motor impairments in Parkinson's disease (PD). The aims of this study were to: 1) assess differences between in-clinic and in-home gait speed, and sit-to-stand and stand-to-sit duration in PD patients (in comparison with healthy controls); and 2) determine the objective physical activity measures, including gait, postural balance, instrumented Timed-up-and-go (iTUG), and in-home spontaneous physical activity (SPA), with the highest correlation with subjective/semi-objective measures, including health survey, fall history (fallers vs. non-fallers), fear of falling, pain, Unified Parkinson's Disease Rating Scale, and PD stage (Hoehn and Yahr). Objective assessments of motor performance were made by measuring physical activities in the same sample of PD patients (n = 15, Age: 71.2±6.3 years) and age-matched healthy controls (n = 35, Age: 71.9±3.8 years). The association between in-clinic and in-home parameters, and between objective parameters and subjective/semi-objective evaluations in the PD group was assessed using linear regression-analysis of variance models and reported as Pearson correlations (R). Both in-home SPA and in-clinic assessments demonstrated strong discriminatory power in detecting impaired motor function in PD. However, mean effect size (0.94±0.37) for in-home measures was smaller compared to in-clinic assessments (1.30±0.34) for parameters that were significantly different between PD and healthy groups. No significant correlation was observed between identical in-clinic and in-home parameters in the PD group (R = 0.10-0.25; p>0.40), while the healthy showed stronger correlation in gait speed, sit-to-stand duration, and stand-to-sit duration (R = 0.36-0.56; p
- Kuo, P. H., Lei, H. H., Avery, R., Krupinski, E. A., Bauer, A., Sherman, S., McMillan, N., Seibyl, J., & Zubal, G. I. (2014). Evaluation of an Objective Striatal Analysis Program for Determining Laterality in Uptake of ¹²³I-Ioflupane SPECT Images: Comparison to Clinical Symptoms and to Visual Reads. Journal of nuclear medicine technology, 42(2), 105-8.More infoAn automated objective striatal analysis (OSA) software program was applied to dopamine transporter (123)I-ioflupane images acquired on subjects with varying severities of parkinsonism. The striatal binding ratios (SBR) of the left and right putamina (relative to the occipital lobe) were computed, and the laterality of that measure was compared with clinical symptoms and visual reads. The objective over-read of OSA was evaluated as an aid in confirming the laterality of disease onset.
- Kuo, P. H., Avery, R., Krupinski, E., Lei, H., Bauer, A., Sherman, S., McMillan, N., Seibyl, J., & Zubal, G. (2013). Receiver-operating-characteristic analysis of an automated program for analyzing striatal uptake of 123I-ioflupane SPECT images: calibration using visual reads. Journal of nuclear medicine technology, 41(1), 26-31.More infoA fully automated objective striatal analysis (OSA) program that quantitates dopamine transporter uptake in subjects with suspected Parkinson's disease was applied to images from clinical (123)I-ioflupane studies. The striatal binding ratios or alternatively the specific binding ratio (SBR) of the lowest putamen uptake was computed, and receiver-operating-characteristic (ROC) analysis was applied to 94 subjects to determine the best discriminator using this quantitative method.
- Francis, B. A., Wang, M., Lei, H., Du, L. T., Minckler, D. S., Green, R. L., & Roland, C. (2005). Changes in axial length following trabeculectomy and glaucoma drainage device surgery. The British journal of ophthalmology, 89(1), 17-20.More infoThis study examines the changes in axial length (AL) after trabeculectomy and glaucoma drainage device (GDD) surgery and enabled an equation to be derived allowing prediction of AL change after filtering surgery.
- Lei, H. (2003). Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Ophthalmology, 110(5), 971-8.More infoTo update the findings from the Choroidal Neovascularization Prevention Trial (CNVPT) with respect to resolution of drusen, incidence of choroidal neovascularization, and visual function.
- Lei, H., & Schuchard, R. A. (1997). Using two preferred retinal loci for different lighting conditions in patients with central scotomas. Investigative ophthalmology & visual science, 38(9), 1812-8.More infoUsing a scanning laser ophthalmoscope, it was found that some patients with relative central scotomas reliably used two different preferred retinal loci (PRLs) at different stimulus illuminances. This article describes adaptations in a patient's PRL for fixation when dimming the stimulus increased the relative scotoma size.
Presentations
- Lei, H. (2015, September 26-28). Taking a cosmetic approach to neurological disorders with facial Botulinum toxin injections. The 11th International Congress of Cosmetic Dermatology. China.
Poster Presentations
- Lei, H. (2018, Oct 5-9). Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series. The International Congress of Parkinson’s Disease and Movement Disorders®. Hong Kong.
- Byreddy, S., Zahid, U., & Lei, H. (2017, June/Spring). Abnormal DaTscan in a case of Anoxic brain injury. the 21st International Congress of Parkinson’s Disease and Movement Disorders. Vancouver, BC, Canada.